The relation between bone marrow angiogenesis and the proliferation index Ki-67 in multiple myeloma

Journal of Clinical Pathology

Volumn 57, Issue 8, 2004, Pages 856-860

  Alexandrakis, M G ^a   Passam, F H ^b   Dambaki, C ^a   Pappa, C A ^a   Stathopoulos, E N ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CD34 ANTIGEN; CD38 ANTIGEN; KI 67 ANTIGEN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BONE MARROW; BONE MARROW METASTASIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; ENDOTHELIUM CELL; FEMALE; HEMATOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MICROVASCULARIZATION; MULTIPLE MYELOMA; PATIENT SELECTION; PREMEDICATION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ACUTE DISEASE; ADP-RIBOSYL CYCLASE; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIGENS, CD; ANTIGENS, CD38; BIOLOGICAL MARKERS; BONE MARROW CELLS; C-REACTIVE PROTEIN; CELL DIVISION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; STATISTICS, NONPARAMETRIC;

EID: 4043143471     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2003.013110     Document Type: Article

References (40)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
2. Acenero MJ, Conzales JF, Gallego GM, et al. Vascular enumeration as a significant prognosticator for invasive breast carcinoma. J Clin Oncol 1998;16:1684-8.
3. Folkman J. New perspectives in clinical oncology from angiogenesis research. Eur J Cancer 1996;14:2534-9.
4. Chaudhary R, Bromfey M, Clarke NW, et al. Prognostic relevance of microvessel density in cancer of the urinary bladder. Anticancer Res 1999;19:3479-84.
5. Gallego GM, Acenero MJ, Sanz Ortega J, et al. Vascular enumeration as a prognosticator for colorectal carcinoma. Eur J Cancer 2000;36:55-60.
6. Fox SB. Tumor angiogenesis and prognosis. Histopathology 1997;30:294-301.
7. Moehler TM, Neben K, Ho AD, et al. Angiogenesis in hematologic malignancies. Ann Hematol 2001;80:695-705.
8. Alexandrakis MG, Passam FH, Boula A, et al. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma. Ann Hematol 2003;82:19-23.
9. Laroche M, Brousset P, Ludat I, et al. Increased vascularization in myeloma. Eur J Haematol 2001;66:89-93.
10. Rajkumar SV, Mesa RA, Fonseca R, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy af undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 2002;8:2210-16.
11. Sezer O, Niemoller K, Eucher J, et al. Bone marrow micravessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol 2000;79:574-7.
12. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndrome. Blood 2000;150:2240-5.
13. Perez-Atayde AR, Sallan SE, Tedrow U, et al. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997;150:815-21.
14. Padro T, Ruiz S, Bieker R, et al. Increased angiogenesis in the bone marrow of patients with acute leukemia. Blood 2000;95:2637-44.
15. Bruneri G, Bertolini F, Soligo D, et al. Angiogenesis in myelodysplastic syndromes. Br J Cancer 1999;81:1398-401.
16. Vacca A, Ribatti D, Ruco L, et al. Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non Hodgkin's lymphomas. Br J Cancer 1999;79:965-70.
17. Sezer O, Niemoller K, Jacob C, et al. Relationship between bone marrow angiogenesis and plasma cell infiltration and serum B2-microglobulin levels in patients with multiple myeloma. Ann Hematol 2001;80:598-601.
18. Rajkumar SV, Leong T, Roche PC, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000;6:3111-16.
19. Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994;87:503-8.
20. Thaler J, Fechner F, Herold M, et al. Interleukin-6 in multiple myeloma: correlation with disease activity and Ki-67 proliferation index. Leuk Lymphoma 1994;12:265-71.
21. Schluter C, Duchrow M, Wohlenberg C, et al. The cell proliferation- associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining protein. J Cell Biol 1993;123:513-22.
22. Kanavaros P, Stefanaki K, Vlachonikolis J, et al. Immunohistochemical expression of the p53, p21/waf-1, Rb, p16 and Ki-67 proteins in multiple myeloma. Anticancer Res 2000;20:4619-26.
23. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma; correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975;36:842-54.
24. Papadaki H, Kyriakou D, Foudoulakis A, et al. Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity. Acta Haematol 1997;97:191-5.
25. Cordell JL, Falini B, Erber WN, et al. Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APPAP complexes). J Histochem Cytochem 1984;32:219-29.
26. Miguel-Garcia A, Matutes E, Tarin F, et al. Circulating Ki67 positive lymphocytes in multiple myeloma and benign monoclonal gammopathy. J Clin Pathol 1995;48:835-9.
27. San Miguel JF, Sanchez J, Gonzalez M. Prognostic Factors and classification in multiple myeloma. Br J Cancer 1989;59:113-18.
28. Goodson WH, Moore DH, Ljung BM, et al. The prognostic value af proliferation indices: a study with in vivo bromodeoxyuridine and Ki-67. Breast Cancer Res Treat 2000;59:113-23.
29. Sezer O, Niemoller K, Kaufmann O, et al. Decrease of bone marrow angiogenesis in myeloma patients achieving a remission after chemotherapy. Eur J Haematol 2001;66:238-44.
30. Hotchkiss KA, Ashton AW, Mahmood R, et al. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center. Mol Cancer Ther 2002;1:1191-200.
31. Oh HS, Choi JH, Park CK, et al. Comparison of microvessel density before and after peripheral blood stem cell transplantation in multiple myeloma patients and its clinical implications: multicenter trial. Int J Hematol 2002;76:465-70.
32. O'Leary JJ, Shapiro RL, Ren CJ, et al. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin Cancer Res 1999;5:181-7.
33. Kumar S, Fonseca R, Dispenzieri A, et al. Bone marrow angiogenesis in multiple myeloma: effect of therapy. Br J Haematol 2002;119:665-71.
34. Lakhorst HM, Boom SE, Terpstra W, et al. Determination of the growth fraction in monoclonal gammopathy with the monoclonal antibody Ki-67. Br J Haematol 1988;69:477-81.
35. Drach J, Gattringer H, Classl H, et al. The biological and clinical significance of the Ki-67 growth fraction in multiple myeloma. Hematol Oncol 1992;10:125-34.
36. Girino M, Riccardi A, Luoni R, et al. Monoclonal antibody Ki-67 as a marker of proliferative activity in monoclonal gammopathies. Acta Haematol 1991;5:26-30.
37. Pellegrini W, Facchetti F, Marocolo D, et al. Assessment of cell proliferation in normal and pathological bone marrow biopsies: a study using double sequential immunophenotyping on paraffin sections. Histopathology 1995;27:397-405.
38. Rawstron A, Barrans S, Blythe D, et al. Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression. Br J Hematol 1999;104:138-43.
39. Alexandrakis MG, Passam FH, Ganotakis ES, et al. The clinical and prognostic significance of erythrocyte sedimentation rate (ESR) serum interleukin-6 (IL-6) and acute phase protein levels in multiple myelomo. Clin Lab Haem 2003;25:41-6.
40. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71.